In this study, patients receiving five to six cycles of Ra-223 had better prognosis profiles based on a lower burden of metastatic disease, a lower percentage of these patients had received prior docetaxel, less severe baseline bone pain, a lower percentage of patients with an ECOG-PS2, and lower PSA and ALP values. Here, KLK3 is linked to metastatic neoplasm.